A preclinical characterization of Retatrutide focus on GCGR-mediated adenylate cyclase activation, intracellular cyclic AMP (…
Preclinical investigation into GCGR binding kinetics and cAMP-mediated lipid mobilization pathways of Retatrutide in rodent models.
A study of retatrutide receptor internalization kinetics and cAMP profiles in islet and hepatic models.
A precise molecular and tissue-specific investigation of Retatrutide signaling kinetics and cellular responses in vitro.
A preclinical analysis examining GLP-1R receptor trafficking kinetics and endosomal sorting dynamics of Retatrutide in beta-cell assays.
A preclinical mechanistic overview of Retatrutide co-activation kinetics on GLP-1R, GIPR, and GCGR and downstream lipid-oxidation signaling.
An in-depth, systems-level preclinical research synthesis of Retatrutide’s co-activation kinetics on GLP-1R, GIPR, and GCGR.
Triple Agonist Affinity: Decoding Retatrutide’s Co-Activation Kinetics on GLP-1R, GIPR, and GCGR
← Back to The Retatrutide Report Triple Agonist Affinity: Decoding Retatrutide’s Co-Activation Kinetics on GLP-1R, GIPR, and GCGR Section 1: Compound Overview Retatrutide (LY3437943; Eli Lilly) is a synthetic 39-amino acid peptide conjugated to a C20 fatty diacid moiety via a linker at lysine residue 20. This lipid conjugation confers albumin binding, extending the plasma […]
Retatrutide, designated by its investigational identifier LY3437943, is a synthetic, unimolecular peptide engineered to function as a simultaneous agonist at three distinct G-protein-coupled receptor (GPCR) systems: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR).
This preclinical literature review examines the structural basis of Retatrutide binding to glucagon receptors and subsequent mitochondrial lipid beta-oxidation pathways.